Crossmark

Severe toxicity of capecitabine in a patient with DPD deficiency after a safe FEC-100 experience: why we should test DPD deficiency in all patients before high-dose fluoropyrimidines

Crossref DOI link: https://doi.org/10.1007/s00280-021-04233-1

Published Online: 2021-02-15

Published Print: 2021-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Maillard, Maud

Eche-Gass, Audrey

Ung, Mony

Brice, Aurélie

Marsili, Sabrina

Montastruc, Marion

Puisset, Florent

Thomas, Fabienne https://orcid.org/0000-0001-9886-412X
License Information

Text and Data Mining valid from 2021-02-15

Version of Record valid from 2021-02-15
More Information

Article History

Received: 18 December 2020

Accepted: 12 January 2021

First Online: 15 February 2021

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

: The patient signed a consent form allowing the use of her biological results and samples for research purpose.

: The patient signed informed consent regarding publishing her data<i>.</i>

Document is current

Any future updates will be listed below